Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy.

The number and time to appearance of pulmonary metastases were evaluated in 15 patients with osteogenic sarcoma receiving adjuvant chemotherapy with high-dose methotrexate and doxorubicin (adjuvant group). The results were compared to 33 age- and sex-matched controls (control group). The adjuvant group demonstrated a reduction in the number and a delay in the appearance of the metastases. The median time to development of metastases was 17 mo in the adjuvant group and 7 mo in the control group, and the median number of metastases was 2 and 12, respectively.

Download Full-text

Adjuvant chemotherapy for osteogenic sarcoma in childhood. Three years experience with high-dose methotrexate/citrovorum-factor rescue, adriablastin, and endoxan

Journal of Pediatric Surgery ◽

10.1016/s0022-3468(80)80500-8 ◽

1980 ◽

Vol 15 (1) ◽

pp. 113

Author(s):

Karl-Ludwig Waag

Keyword(s):

Adjuvant Chemotherapy ◽

Osteogenic Sarcoma ◽

High Dose ◽

High Dose Methotrexate ◽

Dose Methotrexate

Download Full-text

Combined Surgery and Adjuvant Chemotherapy with High Dose Methotrexate and Folinic Acid Rescue (HDMTX-CF) for Infiltrating Tumours of the Bladder

British Journal of Urology ◽

10.1111/j.1464-410x.1981.tb03226.x ◽

1981 ◽

Vol 53 (5) ◽

pp. 439-443 ◽

Cited By ~ 18

Author(s):

Y. Socquet

Keyword(s):

Adjuvant Chemotherapy ◽

Folinic Acid ◽

High Dose ◽

High Dose Methotrexate ◽

Combined Surgery ◽

Dose Methotrexate ◽

Folinic Acid Rescue

Download Full-text

A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma.

Journal of Clinical Oncology ◽

10.1200/jco.1984.2.3.152 ◽

1984 ◽

Vol 2 (3) ◽

pp. 152-156 ◽

Cited By ~ 83

Author(s):

J H Edmonson ◽

S J Green ◽

J C Ivins ◽

G S Gilchrist ◽

E T Creagan ◽

...

Keyword(s):

Pilot Study ◽

Adjuvant Chemotherapy ◽

High Dose ◽

High Dose Methotrexate ◽

Term Survival ◽

Dose Methotrexate ◽

Primary Osteosarcoma ◽

Chemotherapy Patients ◽

One Year

Thirty-eight patients whose primary extremity or limb girdle osteosarcomas had been completely excised (37 amputations, one limb sparing procedure) were allocated at random to two treatment groups receiving respectively regular follow-up examinations plus a high-dose methotrexate (HDMTX) regimen or regular follow-up without primary adjuvant chemotherapy. Although the vincristine, HDMTX, leucovorin regimen was generally quite tolerable when given at three-week intervals for one year and most of the chemotherapy patients followed the planned HDMTX dose escalations from 3 to 6 to 7.5 g/m2, delayed methotrexate excretion limited dosage escalations in 25%. An estimated 52% of the 38 patients were surviving five years after randomization and an estimated 42% remained continuously relapse-free after five years. No significant differences between the outcomes of the 20 treated and the 18 untreated patients were apparent; however, power to detect differences was low. Furthermore, no significant differences in postmetastasis survival were apparent between the 12 treated and 10 untreated patients who relapsed. Approximately 20% of these failing patients appear to have been salvaged for long-term survival. This pilot study of HDMTX confirms the continuing need for controlled clinical trials in determining the therapeutic value of adjuvant chemotherapy programs for patients with primary osteosarcoma.

Download Full-text